# A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Source: https://onco.cc/trials/nct04458272/  
OnCo record `nct04458272` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Safusidenib in glioma & glioblastoma, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.

## Summary

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma is a phase 2 interventional study registered as NCT04458272 by Daiichi Sankyo Co., Ltd., with 25 participants enrolled, started 2020-07-08 and due to reach its primary completion in 2023-03-10. Interventions recorded: DS-1001b.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04458272
- Phase: 2
- Setting: A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma
- Sponsor: Daiichi Sankyo Co., Ltd.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT04458272: https://clinicaltrials.gov/study/NCT04458272

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Safusidenib](https://onco.cc/drugs/safusidenib/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct04458272.json